In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed the day trading at $434.23 down -0.49% from the previous closing price of $436.38. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 1.73 million shares were traded. ALNY stock price reached its highest trading level at $444.67 during the session, while it also had its lowest trading level at $420.3454.
Ratios:
For a better understanding of ALNY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 259.16. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 11.86 whereas as Long-Term Debt/Eq ratio is at 11.17.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when Fitzgerald Kevin Joseph sold 12,128 shares for $452.18 per share. The transaction valued at 5,483,990 led to the insider holds 21,264 shares of the business.
Fitzgerald Kevin Joseph bought 12,128 shares of ALNY for $5,445,472 on Nov 17 ’25. On Nov 12 ’25, another insider, Greenstreet Yvonne, who serves as the Chief Executive Officer of the company, sold 15,650 shares for $453.69 each. As a result, the insider received 7,100,322 and left with 65,409 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 57367785472 and an Enterprise Value of 57416466432. As of this moment, Alnylam’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1806.28, and their Forward P/E ratio for the next fiscal year is 58.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.87 while its Price-to-Book (P/B) ratio in mrq is 244.67. Its current Enterprise Value per Revenue stands at 17.886 whereas that against EBITDA is 178.856.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.32, which has changed by 0.7224393 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $495.55, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is -4.94%, while the 200-Day Moving Average is calculated to be 24.09%.
Shares Statistics:
Over the past 3-months, ALNY traded about 1.08M shares per day on average, while over the past 10 days, ALNY traded about 903590 shares per day. A total of 131.79M shares are outstanding, with a floating share count of 129.75M. Insiders hold about 1.79% of the company’s shares, while institutions hold 99.34% stake in the company. Shares short for ALNY as of 1761868800 were 3769098 with a Short Ratio of 3.48, compared to 1759190400 on 3507540. Therefore, it implies a Short% of Shares Outstanding of 3769098 and a Short% of Float of 3.75.
Earnings Estimates
. The current assessment of Alnylam Pharmaceuticals Inc (ALNY) involves the perspectives of 11.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $2.09, with high estimates of $2.55 and low estimates of $1.55.
Analysts are recommending an EPS of between $5.99 and $3.76 for the fiscal current year, implying an average EPS of $4.96. EPS for the following year is $10.61, with 12.0 analysts recommending between $13.86 and $6.44.
Revenue Estimates
20 analysts predict $1.17B in revenue for. The current quarter. It ranges from a high estimate of $1.61B to a low estimate of $1.04B. As of. The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $593.17MFor the next quarter, 20 analysts are estimating revenue of $1.22B. There is a high estimate of $1.31B for the next quarter, whereas the lowest estimate is $1.11B.
A total of 24 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $4.23B, while the lowest revenue estimate was $3.42B, resulting in an average revenue estimate of $3.74B. In the same quarter a year ago, actual revenue was $2.25BBased on 23 analysts’ estimates, the company’s revenue will be $5.33B in the next fiscal year. The high estimate is $6.12B and the low estimate is $4.34B.
